The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer - A Pilot Study
The investigators propose to evaluate Molecular Breast Imaging in patients undergoing
neoadjuvant therapy for breast cancer with the aims to document that 1) the change in
uptake of 99mTc-sestamibi prior to initiation of neoadjuvant therapy, after 3-5 weeks of
neoadjuvant therapy and at completion of neoadjuvant therapy prior to breast cancer surgery
will be a reflection of the tumor response to neoadjuvant therapy.
2) Tumor response at 3-5 weeks of neoadjuvant therapy is predictive of tumor response at
completions of neoadjuvant therapy.
3) Post-neoadjuvant tumor size as determined by MBI corresponds to size found at surgery.
Observational Model: Case-Only, Time Perspective: Prospective
Dietlind L. Wahner-Roedler, M.D.
United States: Institutional Review Board
|Mayo Clinic - Rochester||Rochester, Minnesota 55905|